title: [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
abstract: BACKGROUND
  Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them in chemical structure, mechanism of activity and therapeutic effects. To explore the efficacy and side effects of icotinib hydrochloride in the treatment of the advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation and wild-type.
  
  
  METHODS
  Patients with advanced NSCLC who were treated with icotinib hydrochloride in Beijing Chest Hospital were retrospective analyzed from March 2009 to December 2014.
  
  
  RESULTS
  The clinical data of 124 patients (99 with EGFR mutation and 25 with wild type) with advanced NSCLC were enrolled in this study. The patients' overall objective response rate (ORR) was 51.6 % and the disease control rate (DCR) was 79.8%; The patients with EGFR mutation, ORR was 63.6%, DCR was 93.9%. The ORR was 4.0% and the DCR was 24.0% in the wild-type patients. Median progression-free survival (PFS) with icotinib treatment in EGFR mutation patients was 10.5 months and 1.0 month in wild-type patients. The major adverse events were mild skin rash (30.6%) and diarrhea (16.1%).
  
  
  CONCLUSIONS
  Monotherapy with icotinib hydrochloride is effective and tolerable for the advanced NSCLC EGFR mutation patients.
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Na
authors.initials: N
authors.lastname: Qin
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Jinghui
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Xinjie
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Xinyong
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Jialin
authors.initials: J
authors.lastname: Lv
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Jingying
authors.initials: J
authors.lastname: Nong
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Quan
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Shucai
authors.initials: S
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D002681:China; D043844:Crown Ethers / Q000008:administration & dosage*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011799:Quinazolines / Q000008:administration & dosage*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D043844:Crown Ethers; D011799:Quinazolines; C531470:icotinib; C512478:EGFR protein, human; D066246:ErbB Receptors